Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer
“We continue to bolster our intellectual property portfolio for REQORSA, understanding that our lead drug candidate may benefit patients with many types of cancers,” said Thomas Gallagher, Esq., Senior Vice President of Intellectual Property and Licensing at Genprex. “Positive preclinical data indicate that REQORSA in combination with ALK inhibitors may provide benefit to patients with ALK-positive (ALK+) lung cancer. We are pleased to be able to protect this drug combination for a new subset of lung cancer patients, which widens our exclusivity of drug combinations with REQORSA and enhances our intellectual property position.”
Share:
More News
“CTT2274 has a unique structure and linker that maximizes tumor uptake and allows for release of the chemotherapeutic drug only within the tumor cell thus minimizing potential side effects from the chemotherapy. No other prodrug like this is being developed for prostate cancer and CTT2274 holds great promise as a
“HLX22-GC-301 is a double-blind, randomized, controlled multicenter phase 3 study aims to compare the efficacy and safety of HLX22 in combination with trastuzumab and chemotherapy versus trastuzumab and chemotherapy with or without pembrolizumab as first-line treatment in patients with human epidermal growth factor receptor 2 (HER2)-positive, locally advanced or metastatic
“We are encouraged by the consistent complete response rates observed in our expanded patient cohort,” said Patrick Soon-Shiong, M.D., Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio. “These results highlight the potential of ANKTIVA to transform the treatment landscape for patients with BCG-unresponsive NMIBC CIS, offering hope
“The collaborative End-of-Phase 2 meeting with the FDA represents another important milestone in our IMNN-001 clinical program, and we are very pleased that the Agency is aligned with the potential for IMNN-001 to address a significant unmet need in ovarian cancer treatment and our Phase 3 plans,” said Stacy Lindborg,
